[495] Virologic Response at Treatment Month 12 May Predict Sustained Antiviral Efficacy in Adefovir Treated Lamivudine-Resistant Chronic Hepatitis B

Han, W.S.; Yeon, J.E.; Kim, Y.H.; Oh, Seungeun; Seo, Yousuke; Yim, H.J.; Choe, Won Hyeok; Kwon, Seog Woon; Byun, K.S.; Lee, C.H.

doi:10.1016/s0168-8278(07)62093-5

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study involving 146 HBeAg-positive patients with lamivudine resistance showed that a decrease in serum HBV DNA<2 log 10 copies/ml at week 24 of adefovir therapy was associated with a significantly lower rate of undetectable HBV DNA at 1 year of treatment (23.3% versus 44%) [45]. A study involving 204 patients with lamivudine resistance showed that month 12 HBV DNA<4 log 10 copies/ml was associated with a higher HBeAg seroconversion rate (40% versus 27%, P<0.05) at month 24 during adefovir monotherapy [46].…”

Section: Prediction Of Long-term Virological Responsementioning

confidence: 99%

“…In patients with lamivudine resistance, a Korean study involving 146 HBeAg-positive patients showed that a decrease of serum HBV DNA by <2 log 10 copies/ml at week 24 of adefovir therapy was significantly (odds ratio 2.46, 95% confidence interval 1.09-5.55, P<0.05) associated with genotypic adefovir resistance [45]. Another Korean study involving 204 patients with lamivudine resistance showed that month 12 HBV DNA levels <4 log 10 copies/ml were associated with a low rate of genotypic adefovir resistance (21% versus 42%, P=0.014) at month 24 after switching to adefovir monotherapy [46]. Another study involving 128 patients with lamivudine resistance showed that serum HBV DNA>10 6 copies/ml at week 48 of adefovir therapy (add-on in 90 patients and monotherapy in 38 patients) was associated with a higher incidence (12.5% versus 2.9%, P<0.05) of genotypic adefovir resistance [51].…”

Section: Prediction Of Drug Resistancementioning

confidence: 99%

See 1 more Smart Citation

On-Treatment Outcome Prediction and Adjustment during Chronic Hepatitis B Therapy: Now and Future

Liaw

2009

Antiviral Therapy

View full text Add to dashboard Cite

Studies published to date regarding on-treatment outcome prediction during chronic hepatitis B therapy were reviewed. Studies have shown that initial virological responses in terms of week 24 serum hepatitis B virus (HBV) DNA levels are associated with therapeutic outcomes of 1-year pegylated interferon-α and entecavir therapy, and weeks 52 or 104 of lamivudine and telbuvudine therapy. HBV DNA levels at week 48 are also associated with long-term adefovir therapy outcomes. Conceptual on-treatment adjustment and strategies have been proposed; however, this approach seems only necessary during therapy with nucleos(t)ide analogues with substantial risk of drug resistance. In addition, studies are needed to decide whether switching to or adding on a second drug, and with which drug, is the most cost-effective strategy.

show abstract

Section: Prediction Of Long-term Virological Responsementioning

confidence: 99%

Section: Prediction Of Drug Resistancementioning

confidence: 99%